Skip to main content

Table 2 Systemic treatment of metastatic sarcoma by line

From: Treatment patterns and survival in an exhaustive French cohort of pazopanib-eligible patients with metastatic soft tissue sarcoma (STS)

 

1st systemic treatment line

2nd systemic treatment line

3rd systemic treatment line

4th systemic treatment line

N = 107

N = 59

N = 34d

N = 18

Clinical triala

 Yes

36 (33.6%)

16 (27.1%)

9 (27.3%)

0 (0.0%)

 No

71 (66.4%)

43 (72.9%)

24 (72.7%)

18 (100.0%)

Treatment classa

 Cytotoxic agent

65 (91.6%)b

37 (86.0%)b

22 (91.7%)b

12 (66.6%)b

 Hormonal therapy

2 (2.8%)

1 (2.3%)

0 (0.0%)

0 (2.4%)

 Targeted therapy

4 (5.6%)

5 (11.7%)

2 (8.3%)

6 (33.4%)

Treatment combinationsa

 Monotherapy

38 (53.5%)

30 (69.8%)

9 (37.5%)

17 (94.4%)

 Combination

33 (46.5%)

13 (30.2%)

15 (62.5%)

1 (0.6%)

Individual agenta,c

 Doxorubicin

46 (64.7%)

10 (23.3%)

1 (4.2%)

0 (0.0%)

 Ifosfamide

17 (23.9%)

6 (14.0%)

3 (12.5%)

1 (5.5%)

 Dacarbazine

8 (11.3%)

1 (2.3%)

1 (4.2%)

0 (0.0%)

 Gemcitabine

11 (15.5%)

11 (25.6%)

12 (50.0%)

2 (11.1%)

 Docetaxel

11 (15.5%)

10 (23.3%)

10 (41.7%)

0 (0.0%)

 Trabectedin

2 (2.8%)

9 (20.9%)

4 (16.4%)

7 (38.9%)

At least one off-label agent

 Yes

27 (38.0%)

20 (46.5%)

20 (83.3%)

11 (61.1%)

 No

44 (62.0%)

23 (53.5%)

4 (16.3%)

7 (38.9%)

  1. apercentages are calculated with respect to the total number of patients receiving chemotherapy
  2. bCertain patients (3 at 1st line, & at 2nd line, 2 at 3rd line and 2 at 4th or higher line) received a combination of a cytotoxic agent and a targeted therapy, the classes of treatment used are therefore not mutually exclusive
  3. cOnly the most frequently used agents are listed; these drugs are frequently used in combinations, so the drugs are not mutually exclusive
  4. dTherapy data missing on 1 patient